News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Hepatitis C treatment side-effects
Vertex hepatitis C drug Incivek gets 'black box' warning over possible fatal skin conditions

The FDA says patients taking the pill in combination with two other treatments should stop immediately if they develop a rash that grows worse or comes with symptoms like a fever, diarrhea or mouth sores.

Published
20 December 2012
From
Washington Post
Hepatitis C - First Interferon-Free Regimens Expected to Launch in 2014 in the United States and Europe

The first IFN-free regimens are expected to launch in the United States and Europe by 2014 and, once available, Decision Resources anticipates aggressive and widespread uptake of these therapies in patients who are treatment-naive as well as treatment-experienced.

Published
19 December 2012
From
HCV New Drugs Research
Pharmaceutical industry
Breaking Up With Gilead Sciences

Eventually, even perpetually bullish Wall Street analysts are going to realize the hepatitis C market is far smaller than current estimates suggest.

Published
17 December 2012
From
The Street
New and experimental hepatitis C treatment
Is a simple sofosbuvir plus ribavirin regimen suitable for difficult-to-treat hepatitis C patients?

An all-oral dual regimen of sofosbuvir (GS-7977) plus full-dose ribavirin was well-tolerated and produced four-week post-treatment sustained response in approximately three-quarters of previously untreated genotype 1 chronic hepatitis C

Published
12 December 2012
By
Liz Highleyman
Pharmaceutical industry
ITPC Open letter from activists in EECA about the Galien Prix Award goint to Merck for boceprevir

November 30, representatives of ECUO and ITPCru on behalf of the Community Advisory Board in Eastern Europe and Central Asia sent an open letter of protest to the Committee of the Prix Galien expressing their concern with regard to the Galien Award going to Merck for their Hep C drug boceprevir. 

Published
06 December 2012
From
EATG
New and experimental hepatitis C treatment
Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring

Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis)

Published
05 December 2012
By
Liz Highleyman
New and experimental hepatitis C treatment
Monoclonal antibody GS-6624 well tolerated by patients with hepatic fibrosis in initial safety study

Patients with hepatic fibrosis treated with monoclonal antibody GS-6624 experienced reductions to AST and ALT levels with no serious adverse events, treatment discontinuations or dose adjustments in a study presented at The Liver Meeting.

Published
04 December 2012
From
Healio Hepatology
New and experimental hepatitis C treatment
Telaprevir and VX-222 pair well in interferon-free regimen, VX-135 on the horizon

An all-oral regimen of telaprevir, VX-222 and ribavirin for 12 weeks was generally well-tolerated and produced sustained virological response in approximately 70% of previously untreated chronic hepatitis C

Published
03 December 2012
By
Liz Highleyman
New and experimental hepatitis C treatment
Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients

POSITRON Demonstrates Efficacy of a 12-Week All-Oral Regimen of Sofosbuvir Plus Ribavirin for Chronic Hepatitis C Patients who are Unable or Unwilling to Take Interferon

Published
27 November 2012
From
Gilead press release
Hepatitis C treatment
Telaprevir twice-daily works as well as every eight hours, safe for hepatitis C patients with cirrhosis

The hepatitis C protease inhibitor telaprevir (Incivo or Incivek) taken twice daily with pegylated interferon plus ribavirin is as likely to produce sustained virological suppression as the

Published
23 November 2012
By
Liz Highleyman
← Prev1...23456...28Next →

Filter by country